Evidence map›Paper›PMID 32436761›Full record

Trial reportJournal of psychopharmacology (Oxford, England)2020

Glyceryl trinitrate in first-episode psychosis unmedicated with antipsychotics: A randomised controlled pilot study.

Kate Merritt, Ana Catalan, Samuel Cowley, Arsime Demjaha, Matthew Taylor, Philip McGuire, Ruth Cooper, Paul Morrison

Registry-linked trialOpen access · bronzeAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Journal of psychopharmacology (Oxford, England), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02906553 (The Role of Nitric Oxide in Cognition in Schizophrenia; The NOC Study), which is not on this map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.9field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02906553 nacompletednot on this map

The Role of Nitric Oxide in Cognition in Schizophrenia; The NOC Study (Nitric Oxide in Cognition)

TypeinterventionalSponsorKing's College LondonRan2016 to 2019Enrolled19ConditionsSchizophrenia, Psychotic DisordersArmsGlyceryl Trinitrate, Placebo
3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Cognitive Deficit in Schizophrenia: From Etiology to Novel Treatments.International journal of molecular sciences · 2021
    Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 2 countries.

Kate MerrittDepartment of Psychosis Studies, Institute of Psychiatry, Psychology & Neuroscience, London, UK.ORCID 0000-0002-5716-4941
Ana CatalanDepartment of Psychosis Studies, Institute of Psychiatry, Psychology & Neuroscience, London, UK.
Samuel CowleyDepartment of Psychosis Studies, Institute of Psychiatry, Psychology & Neuroscience, London, UK.
Arsime DemjahaDepartment of Psychosis Studies, Institute of Psychiatry, Psychology & Neuroscience, London, UK.
Matthew TaylorDepartment of Psychosis Studies, Institute of Psychiatry, Psychology & Neuroscience, London, UK.ORCID 0000-0003-4716-4662
Philip McGuireDepartment of Psychosis Studies, Institute of Psychiatry, Psychology & Neuroscience, London, UK.
Ruth CooperNewham Centre for Mental Health, Unit for Social and Community Psychiatry, Queen Mary University of London, UK.
Paul MorrisonDepartment of Psychosis Studies, Institute of Psychiatry, Psychology & Neuroscience, London, UK.
Queen Mary University of London · GBUniversity College London · GBUniversity of the Basque Country · ESWarneford Hospital · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThere is a pressing need for new classes of treatment for psychosis. A key therapeutic target for novel compounds is the NMDA receptor, which may be modulated by nitric oxide donors such as sodium nitroprusside (SNP). Recent studies of SNP in patients with psychosis have mixed results, and the drug has to be administered intravenously. Glyceryl trinitrate (GTN) is a well-established cardiovascular medicine that is also a nitric oxide donor, and can be given orally.

aimsWe explored the safety and potential effects of GTN in unmedicated patients with a first episode of psychosis.

methodsThis was a single-centre, randomised, double-blind, placebo-controlled trial from December 2016 to April 2019 (ClinicalTrials.gov identifier: NCT02906553). Patients received 3 × sprays of GTN or placebo for three consecutive days, and were re-assessed on Days 1, 2, 3 and 7. The primary outcome was cognition (Jumping to Conclusions task), secondary outcomes were symptoms (Positive and Negative Syndrome Scale (PANSS)), verbal memory (Hopkins Verbal Learning task), and mood (Bond-Lader Visual Analogue Scales).

resultsNineteen patients were randomised, and 13 participants were included in the analyses. Compared with placebo, GTN was well tolerated, but was not associated with significant effects on cognition, symptoms, or mood. Bayesian statistics indicate that our results were 2× more likely under the null hypothesis than the alternative hypothesis, providing anecdotal evidence that GTN does not improve psychotic symptoms.

conclusionsWe found no indication of an effect of GTN on symptoms of psychosis or cognition.

Indexed as

Outcome Assessment, Health CareAdolescentAdultCognitive DysfunctionDouble-Blind MethodFeasibility StudiesFemaleHumansMaleNitric Oxide DonorsNitroglycerinOral SpraysPilot ProjectsPsychotic DisordersYoung AdultNitric Oxide DonorsNitroglycerinOral SpraysClinical trialglyceryl trinitratepsychosisschizophreniasodium nitroprusside

Identifiers

PMID32436761
PMCPMC7376621
OpenAlexW3022229671

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.